The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium ...

The aim of this study was to perform a persistencebased pharmacoeconomic evaluation of patients receiving antihypertensive drug treatment. Specific objectives were represented by measuring ...

However, when doses 1/3rd or less of the antihypertensive dose are used, patients do not experience the severity of side effects that made the mecamylamine unpopular for the treatment of hypertension.

although its use has been tainted by recent findings from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT was a large, simple trial, designed in a ...

This new medication is intended to be used alongside other antihypertensive drugs for patients whose blood pressure remains uncontrolled. Hypertension affects nearly 120 million adults in the U.S ...

It's important for doctors to be cautious, because overly aggressive antihypertensive treatment can lead to serious health consequences, Bress says. According to a study published by another of ...

High BP is the leading risk factor for death and illness from a cardiovascular event, and managing high BP is a key focus of treatment for cardiovascular diseases. Antihypertensive drugs are widely ...

Daewoong Bio surpasses 10 billion won in antihypertensive drug sales Daewoong Bio reports significant revenue milestone in blood pressure medicine sales ...

New data demonstrated that a cardiovascular polypill—combining a statin with 3 half-standard dose antihypertensive ... analysis projected that polypill treatment would cost $463 per year and ...

Vitamin D3 supplementation was associated with antihypertensive effects without significant between-dose differences among overweight older adults.

MANP was originally discovered by John C. Burnett Jr., MD, Director of the Cardiorenal Research Laboratory at Mayo Clinic. E-Star and Mayo Clinic entered into a worldwide exclusive license agreement ...